# IDEAYA Biosciences (IDYA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/IDYA
## Company Profile
- Ticker: IDYA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 36.04 USD
- Market cap: 2448683840.4 USD
- Last updated: 2026-08-05
## Business Overview
### Precision Oncology Portfolio
IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers.
### Darovasertib in Metastatic Uveal Melanoma
Darovasertib is a protein kinase C inhibitor being developed with crizotinib. The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.
### Broader Uveal Melanoma Development
OptimUM-01 evaluates the darovasertib combination in HLA-A2-positive metastatic disease, while OptimUM-09 studies neoadjuvant treatment in primary uveal melanoma. IDEAYA is also planning the Phase 3 OptimUM-11 trial in the adjuvant setting.
### ADC Pipeline
IDE849 is a DLL3-targeted topoisomerase-1 antibody-drug conjugate in Phase 1/2 development, with a registrational monotherapy trial planned in DLL3-positive tumors. IDE034 is a bispecific B7H3 and PTK7 topoisomerase-1 ADC in early clinical development.
### Synthetic-Lethality Combinations
IDE397 inhibits MAT2A in MTAP-deleted tumors, while IDE892 targets PRMT5. A planned combination cohort will test dual suppression of the methylthioadenosine pathway in biomarker-selected cancers.
## Why The Stock Is Moving

As of Aug 5, 2026, IDYA was little changed and closed at $36.04. No new same-company headline was identified in the current news window.

## Future Catalysts

- Complete OptimUM-02 data in a late-breaking oral presentation at ASCO 2026.
- Completion of the darovasertib NDA filing targeted for the second half of 2026.
- Clinical updates from OptimUM-01, OptimUM-09, IDE849 and IDE034 expected in the second half of 2026.
- Initiation of the IDE892-plus-IDE397 Phase 1 combination cohort planned for mid-2026.
- Initiation of a registrational IDE849 monotherapy trial planned by year-end 2026.

## Recent News
- 2026-08-04 10:00 EST — [IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-bu-9a262261) — Source: IDEAYA Biosciences
- 2026-07-31 10:00 EST — [IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--cf0f42bb) — Source: IDEAYA Biosciences
- 2026-07-27 10:00 EST — [IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-pr-d6c184c3) — Source: IDEAYA Biosciences
- 2026-07-17 13:00 EST — [IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-3e0620d8) — Source: IDEAYA Biosciences
- 2026-06-17 10:00 EST — [IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-dire-49a534d1) — Source: IDEAYA Biosciences